Besides, this model may be experimentally validated to show HR deficiency in cancer, as mentioned by various methods in many recent reports, for instance, a recent study evaluated response of PARP inhibitor using autophagy-proficient and -defective breast cancer cells and xenograft SCID-mice model [31]. The gene discussed is PARP1; the disease is breast carcinoma.